The agreement provides a framework for Invion and Hudson Institute to collaborate on R&D projects based on Invion’s Photosoft technology for the treatment of cancers.
Light-based therapy to kill cancer cells
Invion is developing Photosoft as a next generation photo dynamic therapy (PDT).
PDT uses non-toxic photosensitisers and visible light in combination with oxygen to kill malignant cells, shut down tumours and to stimulate the immune system.
In contrast to surgery, radiotherapy and chemotherapy which are mostly immunosuppressive, PDT causes acute inflammation and invasion of a tumour by leukocytes.
Targeting circulating cancer cells and deeply seated tumours
Photosoft is targeted to address the limitations of first-generation PDT therapies through better solubility and stronger absorption that allows deeper penetration of tissues and better tumour specificity.
Invion’s Photosoft uses a laser light activation method based on short, pulsating ‘near infrared’ (NIR) wavelengths.
It is hypothesised that NIR light therapy allows more effective whole-of-body systemic treatment that can target circulating cancer cells as well as deeply seated tumours.
Initial projects to focus on ovarian cancer
Under the new agreement, Hudson Institute will provide the research facilities and expertise required to undertake individual Invion-sponsored research projects.
Furthermore, Hudson Institute will be responsible for all legislative and professional standards compliance requirements, in accordance with global best practice.
Initial projects will focus on ovarian cancer, and it is envisioned that projects will quickly expand into other cancer indications.
Invion has an agreement with The Cho Group to conduct clinical development of Photosoft globally.
The Cho Group will provide non-dilutive funding to Invion for R&D and clinical trials as part of a global development strategy for the asset.